Ukibu - Company finances
|
EUR
|
2022
From: 2022-11-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | - | 2,505 | 85,868 | 323,101 |
| Profit before tax | -823 | -4,400 | -10,003 | 31,152 |
| Net profit | -823 | -4,400 | -10,003 | 26,876 |
| Equity | 1,677 | -2,723 | -12,725 | 14,151 |
| Liabilities | 823 | 26,662 | 41,206 | 156,114 |
| Non-current assets | 0 | 0 | 0 | 0 |
| Current assets | 2,500 | 23,905 | 28,479 | 170,265 |
| Total assets | 2,500 | 23,905 | 28,479 | 170,265 |
|
Taxes paid
|
||||
| STI taxes | - | 544 | 2,536 | - |
|
Financial indicators
|
||||
| Revenue change y/y | - | - | +3327.9% | +276.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -32.9% | -18.4% | -35.1% | 15.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -49.1% | - | - | 189.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | -175.6% | -11.6% | 8.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | -175.6% | -11.6% | 9.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.5 | - | - | 11.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 1,253 | 42,934 | 161,551 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Ukibu - Social security debts
The company had no debts to Sodra
Ukibu - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Ukibu, UAB (code 306168641) is a Private Limited Liability Company engaged in the retail sale of pharmaceutical products. In the latest financial year, 2025, the company generated revenue of €323.1K and net profit of €26.9K, corresponding to an 8.3% profit margin. This marks a strong improvement from 2024, when revenue was €85.9K and net loss was €10.0K, and from 2023, when revenue was only €2.5K and net loss was €4.4K. Over the two-year period, revenue increased sharply and the business moved from losses to profitability. Total assets at the end of 2025 stood at €170.3K, with equity of €14.2K and liabilities of €156.1K. Asset turnover was 1.90x, indicating a high level of sales relative to assets. Revenue per employee reached €161.6K and profit per employee was €13.4K. Profitability relative to equity was very strong in 2025, while liabilities remained significantly above equity.